Response

Affiliations

¹ Division of Pulmonary and Critical Care Medicine, Rush Medical College and Rush University Medical Center, Chicago, IL. Electronic address: rbalk@rush.edu.
² Critical Care Medicine Department, National Institutes of Health Clinical Center, Bethesda, MD.
³ Premier Research Services, Charlotte, NC.
⁴ Medical Affairs-Americas/East Asia and Global Health Economics and Outcomes, bioMérieux USA, Durham, NC; Medicine and International Relations, University of California San Diego, San Diego, CA; Health Policy and Management, University of North Carolina, Raleigh, NC.

Comment

Robert A Balk et al. Chest. 2017 Jul.

. 2017 Jul;152(1):219-220.

doi: 10.1016/j.chest.2017.04.180.

¹ Division of Pulmonary and Critical Care Medicine, Rush Medical College and Rush University Medical Center, Chicago, IL. Electronic address: rbalk@rush.edu.
² Critical Care Medicine Department, National Institutes of Health Clinical Center, Bethesda, MD.
³ Premier Research Services, Charlotte, NC.
⁴ Medical Affairs-Americas/East Asia and Global Health Economics and Outcomes, bioMérieux USA, Durham, NC; Medicine and International Relations, University of California San Diego, San Diego, CA; Health Policy and Management, University of North Carolina, Raleigh, NC.

No abstract available

Comment on

Effect of Procalcitonin Testing on Health-care Utilization and Costs in Critically Ill Patients in the United States.
Balk RA, Kadri SS, Cao Z, Robinson SB, Lipkin C, Bozzette SA. Balk RA, et al. Chest. 2017 Jan;151(1):23-33. doi: 10.1016/j.chest.2016.06.046. Epub 2016 Aug 25. Chest. 2017. PMID: 27568580 Free PMC article.
Is a Single Initial Procalcitonin Test Sufficient in Septic, Critically Ill Patients to Minimize Antibiotic Use?
van Oers JAH, de Jong E, Beishuizen AB, Nijsten MW, Girbes AR, de Lange DW. van Oers JAH, et al. Chest. 2017 Jul;152(1):218-219. doi: 10.1016/j.chest.2017.03.062. Chest. 2017. PMID: 28693771 No abstract available.

1. Balk R.A., Kadri S.S., Cao Z., Robinson S.B., Lipkin C., Bozzette S.A. Effect of procalcitonin testing on health-care utilization and costs in critically ill patients in the United States. Chest. 2017;151(1):23–33. - PMC - PubMed
1. Kumar A., Roberts D., Wood K.E. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med. 2006;34(6):1589–1596. - PubMed
1. Rhodes A., Evans L.E., Alhazzani W. Surviving Sepsis Campaign: international guidelines for management of sepsis and septic shock: 2016. Crit Care Med. 2017;45(3):486–552. - PubMed
1. De Jong E., van Oers J.A., Beishuizen A. Efficacy and safety of procalcitonin guidance in reducing the duration of antibiotic treatment in critically ill patients: A randomized, controlled, open-label trial. Lancet Infect Dis. 2016;16(7):819–827. - PubMed
1. Prkno A., Wacker C., Brunkhorst F.M., Schlattmann P. Procalcitonin-guided therapy in intensive care unit patients with severe sepsis and septic shock: a systematic review and meta-analysis. Crit Care. 2013;17(6):R291. - PMC - PubMed